

APASL 2012: Echosens introduces the new FibroScan® 502 Touch with CAP™ (Controlled Attenuation Parameter) in Asia

CAP™ is a parameter for steatosis assessment and quantification.

At the 2012 Conference of the Asian Pacific Association for the Study of the Liver (APASL) taking place this year in Taipei from February 16th to February 19th, Echosens, a pioneer and major player in non-invasive hepatic diagnosis, will present for the first time in Asia its latest product, the new FibroScan® 502 Touch, widening the range of FibroScan® devices now available.

Equipped with a new and more ergonomic tactile interface, and based on patented Vibration-Controlled Transient Elastography (VCTE™), the latest FibroScan® provides a reliable, accurate and reproducible assessment of liver tissue stiffness. This technology, developed by Echosens, is unique in measuring liver stiffness at a pre-determined and controlled 50 Hz frequency.

Echosens' FibroScan® 502 Touch represents a quicker and more complete device built around our latest generation of patented liver dedicated elastography engine.

FibroScan® 502 Touch also offers enhanced patient data management with more complete and personalized exam reports.

Continuing Echosens' history of innovation, the FibroScan® 502 Touch is further enhanced by the integration of the latest technological invention: CAP™ (Controlled Attenuation Parameter), a new parameter for steatosis assessment and quantification. Indeed, one of the latest publications¹ underlines the strength of CAP™ performance in detecting steatosis and differentiating steatosis grades. Moreover, this study on patients with chronic hepatitis C, shows that compared to liver biopsy, CAP™ is less prone to sampling error and can explore a liver volume 100 times larger. Both steatosis and fibrosis can be evaluated non-invasively during the same procedure using FibroScan®. ([more about this publication](#))

To learn more about the FibroScan® range, you can meet us at the Echosens Booth (D04-05-06) in the Exhibition Hall during APASL.

You may also visit our website www.echosens.com to let us know how we can support you.

Follow us on Twitter at [FibroScan® by Echosens](#)

Join us on the [FibroScan® by Echosens Facebook](#) page

¹ Sasso et al., *Novel Controlled Attenuation Parameter (CAP™) for non-invasive assessment of steatosis using FibroScan®: validation in chronic hepatitis C*. Journal of viral hepatitis, 2011. **In press.**

Sign up for [Echosens Newsletter](#)

About Echosens and Fibroscan®

FibroScan® is designed to quantify hepatic stiffness and ultrasound attenuation (CAP™) in a non-invasive manner in chronic liver diseases assessment.

Founded in 2001, Echosens supplies its products in more than 70 countries through a global network of suppliers. It dedicates a major portion of its activity to research and development in order to invent new medical devices and open up new medical perspectives. The organization works in close cooperation with health professionals and patients' associations to facilitate management and therapeutic monitoring of patients. To date, there are more than 500 peer-reviewed publications which attest to the efficacy of FibroScan® in clinical practice.

Press Contact

ECHOSENS

Richard GUILLAUME
General Manager

contact@echosens.com

+33 1 44 82 78 50